Enhancing Immunotherapy in High-Risk Neuroblastoma

This grant was awarded in 2024 following an in-depth review of high-quality funding applications by our world class Scientific Advisory Board. Dr. Emmy Dolman from the Children’s Cancer Institute will study the potential for enhancing immunotherapy to treat neuroblastoma. Unlocking Immune Escape: Enhancing Immunotherapy in High-Risk Neuroblastoma via Targeted AURKA Degradation Immunotherapy has transformed cancer […]

Venetoclax combination study

Our world class Scientific Advisory Board strongly recommended we fund this project due to the quality of research and potential to make a difference to treatments. Many of our supporters will be familiar with Dr. Jamie Fletcher from Children’s Cancer Institute and Dr. Toby Trahair from Sydney Children’s Hospital, and the incredible research they lead on high-risk neuroblastoma. In the following video, the team […]